https://www.live-feeds.com/feed/genentech-pays-alector-100m-for-preclinical-parkinson-s-prospectContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/genentech-pays-alector-100m-for-preclinical-parkinson-s-prospecthttps://www.live-feeds.com/feed/genentech-pays-alector-100m-for-preclinical-parkinson-s-prospect#u117616Mon, 12 Oct 2026 09:41:38 +0000Genentech, part of Roche, has agreed to pay Alector $100 million upfront for exclusive worldwide rights to develop and commercialize AL050, an experimental preclinical therapy for Parkinson's disease and other neurodegenerative conditions. The global license agreement could bring Alector up to $1.17 billion in additional conditional development, regulatory, and commercial milestone payments, along with tiered royalties on future sales. AL050 is designed to target GCase deficiency by combining an engineered version of the GCase enzyme with Alector Brain Carrier technology to help cross the